文献速递妇科

瑞典宫颈癌的初始治疗模式与生存:一项基于人群的瑞典妇科癌症组研究

Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study.
PubMed 文献 · Gynecol Oncol · 2019-08-30

该研究基于瑞典妇科癌症质量登记库2011-2015年诊断的宫颈癌患者,分析初始治疗模式与5年相对生存率。研究人群2141例,占全队列2212例的97%,中位随访4.6年,5年年龄标化相对生存率分别为71%和70%。结论认为瑞典宫颈癌初始治疗遵循循证标准,需改进之处包括优化III-IVA期治疗及避免手术与放疗联合。

要点

  • IB1期单纯手术者5年相对生存率95%,同步放化疗者72%,差异有统计学意义(p<0.001)。
  • IIB期同步放化疗+近距离放疗者5年相对生存率77%,单纯放疗+近距离放疗者37%(p=0.045)。
  • III-IVA期仅<40%接受同步放化疗+近距离放疗,其5年相对生存率45%,未接受近距离放疗者为18%(RR 4.1,p<0.001)。

核心结论

  • 瑞典宫颈癌初始治疗遵循循证标准治疗,需改进领域包括优化III-IVA期治疗和避免手术与放疗联合。

研究设计与样本

  • 基于人群的研究,纳入瑞典妇科癌症质量登记库2011-2015年诊断的宫颈癌患者,全队列2212例,研究人群2141例(占97%),主要结局为5年相对生存率。

主要发现

  • 中位随访时间4.6年,研究人群5年年龄标化相对生存率为71%,全队列为70%。
  • IB1期:单纯手术者5年相对生存率95%,同步放化疗者为72%(p<0.001)。
  • IIA1期:74%接受同步放化疗,接受手术者中47%接受了辅助放化疗或放疗。
  • IB2期:手术治疗者5年相对生存率81%(其中69%接受辅助放化疗或放疗),同步放化疗或放疗者为76%(p=0.73)。
  • IIB期:同步放化疗+近距离放疗者5年相对生存率77%,放疗+近距离放疗者为37%(p=0.045),未接受近距离放疗的放疗者为27%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. METHODS: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011-2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. RESULTS: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p < 0.001). In stage IIA1 74% had CT-RT, and 47% of operated patients received adjuvant (CT)-RT. RS stage IB2: surgically treated 81% (69% received adjuvant (CT)-RT) vs. 76% for (CT)-RT (p = 0.73). RS stage IIB: 77% for CT-RT + brachytherapy (BT), 37% for RT + BT (p = 0.045) and 27% for RT-BT (p < 0.001). Stages III-IVA; <40% received CT-RT + BT, RS 45% vs. 18% for RT-BT (RR 4.1, p < 0.001). RS stage IVB 7%. CONCLUSION: Primary treatment of cervical cancer in Sweden adhered to evidence-based standard of care. Areas of improvement include optimising treatment for stages III-IVA, and avoiding combining surgery and radiotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bjurberg M, Holmberg E, Borgfeldt C, et al. Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. Gynecol Oncol. 2019. PMID: 31477283. doi:10.1016/j.ygyno.2019.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。